NASDAQ:PSTV Plus Therapeutics Q3 2025 Earnings Report $3.00 -0.19 (-5.96%) As of 08/20/2026 ProfileEarnings HistoryForecast Plus Therapeutics EPS ResultsActual EPS-$1.00Consensus EPS -$0.50Beat/MissMissed by -$0.50One Year Ago EPSN/APlus Therapeutics Revenue ResultsActual Revenue$1.40 millionExpected Revenue$1.50 millionBeat/MissMissed by -$98.00 thousandYoY Revenue GrowthN/APlus Therapeutics Announcement DetailsQuarterQ3 2025Date10/30/2025TimeBefore Market OpensConference Call DateThursday, October 30, 2025Conference Call Time5:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Plus Therapeutics Earnings HeadlinesCerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business LinesAugust 20 at 7:30 AM | globenewswire.comCerenome Reports Second Quarter 2026 Financial Results and Business UpdateAugust 14, 2026 | globenewswire.comYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe calls it The 10-Minute Guide to Start Trading Options Today, built to help you open your first options trade with less capital than buying shares outright. | True Market Insiders (Ad)Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered LivesAugust 13, 2026 | globenewswire.comPlus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology CompanyJuly 31, 2026 | finanznachrichten.deCerenome Launches as an Integrated CNS Oncology CompanyJuly 31, 2026 | globenewswire.comSee More Plus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email. Email Address About Plus TherapeuticsPlus Therapeutics (NASDAQ:PSTV) is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases. The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors. Plus Therapeutics has secured orphan drug and rare pediatric disease designations for select compounds, reflecting its focus on addressing unmet needs in both adult and pediatric oncology. Clinical studies are conducted in collaboration with academic medical centers and contract research organizations across North America. Headquartered in Austin, Texas, Plus Therapeutics is led by an executive team with extensive experience in radiopharmaceuticals and oncology drug development. The company maintains research, manufacturing and administrative operations in the United States and continues to expand strategic partnerships to advance its targeted radiotherapeutic portfolio.View Plus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx MissMicrosoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?Advance Auto Parts Plunged, But Its Turnaround Is Still WorkingWalmart's Post-Earnings Drop Could Be a Buying Opportunity3 Energy Stocks Raising Dividends as the Sector Surges5 Reasons the S&P 500 Could Keep Rallying Through Year-End Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
